Pfizer, Moderna pledge more mRNA vaccine doses to Europe after AZ supply concerns Bolstered by pandemic-fueled interest, mental health startup Modern Health raises $74M funding round FDA could reject AstraZeneca’s COVID vaccine on efficacy and manufacturing shortfalls: analyst Sanofi invests in health tech firm Novadiscovery, boosting trial simulation platform and COVID-19 work Hims & Hers, Grapevine Health, ATA partner to advance equitable access to virtual care amid COVID-19 Healthcare roundup: Long-term care facilities facing 'business nightmare,' says AHCA/NCAL chief GlaxoSmithKline doubles down on Vir pact, throwing in $345M upfront to go beyond COVID-19 Neurocrine's pandemic play? Leverage marketing to launch Ongentys and keep Ingrezza steady An mRNA vaccine delivered in hydrogel shows promise as a durable cancer immunotherapy Featured Story | By Fraiser Kansteiner After a coronavirus vaccine supply feud between top officials in Europe and COVID-19 vaccine player AstraZeneca, officials there are doubling down on their purchase of an alternative technology. This week, the bloc finalized the purchase of 350 million additional mRNA vaccine doses. read more |
| |
|---|
|
| | Webinar: Mapping the Pathway to Designing Successful Treatments Tuesday, February 23 | 11am ET / 8am PT Experts will introduce Catalent’s new integrated dose form design strategy based on an analyzation of your molecule, patient, and market. Learn how this solution delivers dose form recommendations that can help differentiate your product, improve customer acceptance, and turn your science into patient accepted and commercially successful medicines. Register Now. |
Top Stories By Heather Landi Riding the wave of investor interest in virtual behavioral health startups, Modern Health has closed a $74 million series D investment round. This latest investment brings the company’s total funding to over $170 million in less than two years and raises its valuation to $1.17 billion. read more By Arlene Weintraub It's not just the worrisome data showing AstraZeneca’s COVID-19 vaccine was largely ineffective against the aggressive South African variant that worries some analysts. Inconsistent manufacturing could complicate the company's bid to win over the FDA for a U.S. launch. read more By Ben Adams Sanofi is funneling €2.5 million into French clinical trial simulation specialist Novadiscovery as it looks to beef up its COVID-19 trial response. read more By Brian T. Horowitz With telehealth expanding dramatically during the COVID-19 pandemic, several organizations have banded together to boost access to virtual care for marginalized and underserved communities. The American Telehealth Association, Hims & Hers, Grapevine Health and several others formed the Telehealth Equity Coalition to ensure no one is left behind in the shift to virtual care. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Ben Adams Last year, Big Pharma GlaxoSmithKline and George Scangos’ biotech Vir joined forces against COVID-19. Now, the pair is turning its crosshairs on a broader range of respiratory diseases. read more By Beth Snyder Bulik Diagnosing patients via telehealth can be challenging, but especially when it comes to movement disorders. For Neurocrine Biosciences, that discovery was a double whammy. Two of its key drugs—Ingrezza for the drug-induced disorder tardive dyskinesia and Ongentys for Parkinson’s patients—can be prescribed over video, but uncertainty pushed Neurocrine to get creative. read more By Angus Liu Scientists at China’s National center for Nanoscience and Technology have designed a hydrogel to deliver an mRNA vaccine with an immune-stimulating adjuvant. When injected into mice with melanoma, the vaccine stayed active for at least 30 days, inhibiting tumor growth and preventing metastasis. read more |
